K. Altundag, "Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer," BREAST JOURNAL , vol.23, no.3, pp.376, 2017
Altundag, K. 2017. Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer. BREAST JOURNAL , vol.23, no.3 , 376.
Altundag, K., (2017). Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer. BREAST JOURNAL , vol.23, no.3, 376.
Altundag, Kadri. "Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer," BREAST JOURNAL , vol.23, no.3, 376, 2017
Altundag, Kadri. "Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer." BREAST JOURNAL , vol.23, no.3, pp.376, 2017
Altundag, K. (2017) . "Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer." BREAST JOURNAL , vol.23, no.3, p.376.
@article{article, author={Kadri Altundag}, title={Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer}, journal={BREAST JOURNAL}, year=2017, pages={376} }